TAK 071
Alternative Names: TAK-071Latest Information Update: 26 Feb 2024
Price :
$50 *
At a glance
- Originator Takeda
- Class Antidementias; Antiparkinsonians; Fluorinated hydrocarbons; Isoindoles; Ketones; Nootropics; Pyrazoles; Small molecules
- Mechanism of Action Muscarinic M1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 27 Feb 2023 Takeda completes a phase II trial in Parkinson's disease in USA (PO) (NCT04334317)
- 07 Dec 2022 Phase-II development in Parkinson's disease is still ongoing in USA (PO) (NCT04334317) (Takeda pipeline, December 2022)
- 11 May 2021 Takeda expects approval for Parkinson's disease in FY 2025 (Takeda pipeline, May 2021)